• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Liraglutide
    3 Drugs classified under this active ingredient


    All the Active Ingredient Drugs

    Saxenda
    Novo Nordisk
    RX
    not in the basket chart
    Saxenda

    Human Glucagon-Like Peptide-1. Liraglutide 6 mg/ml.
    PRE-FILL. PENS: 5. Init. 0.6 mg dly.
    Dose should be incr. to 3.0 mg dly. in
    increm. of 0.6 mg with at least one wk.
    interv. to improve GI tolerabil. If escal.
    to the next dose step is not tolerated
    for two consec. wks., consider discont.
    tmt. Dly. doses higher than 3.0 mg are
    not recomm.
    Adults: as adjunct to reduc. cal. diet and
    incr. phys. act. for wt. managt. in pts. BMI
    30 (obes.), or 27 to < 30 (overwt.) and at
    least one comorbidity such as
    dysglycaemia (pre-diabet. or type 2
    diabet. Mellit.), hypertens., or
    dyslipidaemia and who failed wt.
    managt. intervent. Tmt. should be
    discont. aft. 12 wks. on the 3 mg/day
    dose if pts. have not lost at least 5% of
    their initial BW. Adolescents (>12 years)
    as an adjunct to a healthy nutr. and incr.
    phys. act. for wt. managt. in pts. with
    BMI=30. Tmt. should be discont. and
    re-eval. if pts. have not lost at least 4% of
    their BMI or BMI z score after 12 weeks on
    the 3 mg/day or max. toler. dose. Re-eval.
    should be perf. periodic.
    C/I: Hypersens.

    Victoza
    Novo Nordisk
    RX
    partial basket chart
    Victoza

    GLP-1 Receptor Agonist. Liraglutide 6 mg/ml.
    PRE-FILLED PEN (sol. for inject): 30 doses
    of 0.6 mg, 15 doses of 1.2 mg, or 10
    doses of 1.8 mg. Initial: 0.6 mg S.C. 1 x dly for 1 wk, then incr. to 1.2 mg S.C. 1
    x dly for at least 1 wk. Max dose 1.8 mg
    S.C. 1 x dly.
    Tmt. adults with type 2 diabetes mellitus
    to achieve glycem. control. In comb.
    with: Metformin or sulphonylurea, in pts
    with insuff. glycem. control despite max.
    tolerat. dose of monother. with
    metformin or sulphonylurea; In
    combinat. with metformin and a
    sulphonylurea/thiazolidinedione in pts
    with insuff. glycem. control despite dual
    ther.
    C/I: Hypersens.

    Xultophy
    Novo Nordisk
    RX
    partial basket chart
    Multiple ingredients
    Xultophy

    Insulin. Insulin Degludec 100 U/ml, Liraglutide 3.6 mg /ml.
    PRE-FILL. PEN: 1×3 mL (eq.to Insulin
    Degludec 300 UN + Liraglutide 10.8
    mg). The drug  admin.  as dose steps. Add-on to oral glucose-low.  med. products Init.  dose is 10 dose steps (10 units insulin degludec and 0.36 mg liraglutide). One dose step cont. 1 UN of insulin degludec and 0.036 mg of liraglutide. The max. dly. dose is 50 dose steps (50 UN insulin degludec and 1.8 mg liraglutide). The dose counter on the pen shows the number of dose steps. Dosage must be ajust. individ.
    Tmt. of adult.  with type 2 diab. mell.  to improve glycaem.  control in comb. with oral glucose-low. med.  products when these alone or comb. with a GLP-1 receptor ag.  or basal insulin do not provide adeq.  glycaemic control
    C/I: Hypersens.

    CLOSE